vimarsana.com

Substance Use Tom Coderre News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HHS Issues Buprenorphine Practice Guidelines as Study Confirms Access Barriers | Mintz - Health Care Viewpoints

Dept of Health Buprenorphine for Treating Opioid Use Disorder Guidance

Wednesday, June 9, 2021 One of the spillover effects of the COVID-19 pandemic has been the increase in opioid-related deaths. These deaths overwhelmingly affect working-class Americans with limited access and resources to lifesaving drugs such as buprenorphine and naloxone. As a result, the Department of Health and Human Services (HHS) issued the Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder (Practice Guidelines) through a waiver of certain certification requirements prescribed by law. The Practice Guidelines remove a longtime prerequisite tied to training and counseling that several practitioners have cited as a barrier to treating patients with Opioid Use Disorder (OUD). The Practice Guidelines could not come soon enough, as a recent study indicates that individuals with OUD experienced decreased access to treatments during the pandemic.

Federal Grantees May Now Use Funds to Purchase Fentanyl Test Strips | CDC Online Newsroom

(404) 639-3286 The Centers for Disease Control and Prevention (CDC) and the Substance Abuse and Mental Health Services Administration (SAMHSA) announced today that federal funding may now be used to purchase rapid fentanyl test strips (FTS) in an effort to help curb the dramatic spike in drug overdose deaths largely driven by the use of strong synthetic opioids, including illicitly manufactured fentanyl. FTS can be used to determine if drugs have been mixed or cut with fentanyl, providing people who use drugs and communities with important information about fentanyl in the illicit drug supply so they can take steps to reduce their risk of overdose.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.